Skip to main content

AbbVie news and events in 2026

AbbVie is a biopharmaceutical organization that discovers and develops medicines and healthcare solutions. The organization focuses its research and production on therapeutic areas including immunology, oncology, neuroscience, eye care, and aesthetics.

Public (ABBV)Pharmaceutical Manufacturing10,000+ employeesabbvie.comLinkedIn

Get AbbVie's live signals in Claude or ChatGPT, or by API

AskWhat changed at AbbVie this week? Use Autobound signals for abbvie.com.
Dated updates
112
Last event
Nov 17, 2026
Open rolesSnapshot Nov 17, 2026
448
Latest SEC filing
Nov 3, 2026

Source: Autobound Signal API · 112 signals tracked for AbbVie · updated

Overview

AbbVie by topic

Latest events

Latest AbbVie events

  1. Award
    Lymphoma Research Foundation to Honor Leaders in Research, Patient Advocacy and Philanthropy at 2026 Annual GalaAbbVie will receive the Corporate Leadership Award from the Lymphoma Research Foundation at its 2026 Annual Gala.
  2. Investment
    PsiThera Closes $25 Million Financing to Advance Oral Therapeutics in ImmunologyAbbVie Ventures participated as a new investor in PsiThera's $25 million financing round, with Managing Director Claire Leurent joining PsiThera's Board of Directors.
  3. Facility expansion
    AbbVie expands Oxford R&D facility as part of £120 million-plus investmentAbbVie expanded its UK research and development facility in Oxford as part of an investment of more than £120 million.
  4. Revenue
    AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion; Adjusted EPS Reaches $3.82AbbVie reported third-quarter 2026 revenue of $17.404 billion, an increase of 10.3% year over year.
  5. News
  6. In development
    AbbVie (ABBV) Seeks FDA Approval For Etentamig In Multiple MyelomaAbbVie submitted a Biologics License Application to the FDA for its multiple myeloma drug candidate etentamig.
  7. Launch
    U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseaseAbbVie announced that the U.S. FDA approved a subcutaneous induction regimen for SKYRIZI for adults with moderately to severely active Crohn's disease.
  8. In development
    AbbVie unveils positive Phase III results for lutikizumabAbbVie published positive Phase III results evaluating the efficacy and safety of its investigational drug lutikizumab.
  9. In development
    AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO ReadoutsAbbVie reported Phase 2a trial data for its investigational dual-targeting Crohn's disease therapy ABBV-466.
  10. In development
    AbbVie's subcutaneous risankizumab meets Phase III AFFIRM endpointsAbbVie reported Phase III trial results for its subcutaneous induction regimen of risankizumab (Skyrizi) in patients with Crohn's disease.

Showing 10 of 34 events. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track AbbVie with the Signal API

One POST /v1/companies/enrich call with abbvie.com returns every signal type for AbbVie, each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'

Bulk data

Need these signals for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file).

Talk to sales

Same industry

AbbVie questions

What is the latest news on AbbVie?
On Nov 12, 2026, prnewswire.com reported: Lymphoma Research Foundation to Honor Leaders in Research, Patient Advocacy and Philanthropy at 2026 Annual Gala. This page tracks 34 news events for AbbVie since Jul 6, 2026, each with a date and a source link.
What is going on with AbbVie?
In the 90 days to Nov 19, 2026, Autobound tracked 28 news events, 1 10-Q filing, 5 8-K filings, 4 hiring snapshots, 1 deal, 46 signals for AbbVie. The newest story is from Nov 12, 2026 (Award), reported by prnewswire.com.
Has AbbVie announced any acquisitions?
The latest deal story is from Aug 29, 2026. ad-hoc-news.de reported: Karuna Therapeutics stock steady with AbbVie deal and schizophrenia drug progress. The acquisitions page lists 1 deal with a source for each.
What else does Autobound track for AbbVie?
Beyond news and filings, Autobound lists 62+ signals for AbbVie from 7 sources: X (Twitter) (15+), LinkedIn (14), Glassdoor (13), Reddit (11), Patents (6), Conference talks (2), Podcasts (1). See the AbbVie signals page for the dated list.
Is AbbVie hiring right now?
Yes. As of Nov 17, 2026, AbbVie had 448 open roles, and Engineering had the most with 32.

Page updated , the date of the newest row on this page.

Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.

Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.

Data as of .

How this data is built →Get it from the Signal API →